文摘
摘要目的:调查是否类似的白质的变化之间存在(WM)绑定C11-Pittsburgh化合物b(加以)和F18-Flutemetamol (FMT)宠物配体。
背景:宠物与β-amyloid配体分子成像技术正成为针对WM完整性。加以似乎是一个敏感和可靠的宠物配体测量WM完整性,但是鉴于其半衰期短,这不是商用。F18配体如FMT有更长的半衰期可能是一个选择。
设计/方法:认知没有(铜)年长和年轻成人志愿者应对研究的包括广告β-amyloid宠物(N = 61)。个人预期接受了核磁共振,加以和FMT宠物。MRI-FLAIR图像划分为WM hyperintensity(负责人)和正常WM (NAWM)和注册t1加权图像。加以和FMT宠物图像注册t1加权图像。加以吸收和FMT标准价值比率(SUVrs)负责人和NAWM计算使用小脑小腿吸收作为参考。
结果:平均年龄是67岁老年人(61 - 83年)和38年(30-48年)在年轻的成年人。加以和FMT SUVrs年轻铜相比,年长的成年人负责人高(p < 0.001)和NAWM (p < 0.001)。研究负责人和NAWM SUVrs与FMT是高于加以年龄(p < 0.001)和年轻的成年人(p < 0.001),铜。加以和FMT SUVrs NAWM负责人相比高(p < 0.001)和年轻的成年人(p < 0.001),铜。没有明显的区别加以和FMT SUVrs区分负责人从NAWM老和年轻的成年人。
结论:加以和FMT可以成功区分研究负责人和NAWM。研究负责人和NAWM加以和FMT显示类似的地形模式吸收在WM相似年龄的协会。然而,鉴于其半衰期长、商业可用性和更高的约束力的潜力,可以替代加以FMT宠物,专门针对女士。
披露:Zeydan博士的机构已经收到了来自美国国立卫生研究院的研究支持。克里斯托弗·施瓦兹的机构收到NIH的研究支持。斯科特Przybelski没有披露。盖Lesnick已收到个人赔偿作为梅奥诊所的一名雇员。沃尔特·克雷默的机构收到生原体的研究支持。马修Senjem已收到股票或对齐技术的所有权,Inc . .马修Senjem已经收到Inovio生物医学公司股票或所有者权益. .马修Senjem已收到股票或强生公司的所有者权益。马修Senjem已收到股票或台面实验室的所有者权益,Inc . .马修Senjem已收到股票或Nvidia公司的所有者权益。 Matthew Senjem has received stock or an ownership interest from LHC Group, Inc.. Matthew Senjem has received stock or an ownership interest from Natus Medical Incorporated. Matthew Senjem has received stock or an ownership interest from Varex Imaging Corporation. Matthew Senjem has received personal compensation in the range of $100,000-$499,999 for serving as a IT Technical Specialist II with Mayo Clinic. Hoon-Ki Min has nothing to disclose. Brad Kemp has nothing to disclose. The institution of Dr. Jack has received research support from NIH. The institution of Dr. Jack has received research support from Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Dr. Kantarci has nothing to disclose. The institution of Dr. Kantarci has received research support from Eli Lilly. The institution of Dr. Kantarci has received research support from NIH. The institution of Dr. Kantarci has received research support from ADDF. Dr. Lowe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AVID Radiopharmaceutical. Dr. Lowe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Inc. The institution of Dr. Lowe has received research support from AVID Radiopharmaceuticals.
